The EC granted Cell Therapeutics’ Pixuvri® (pixantrone) conditional marketing authorization for use as monotherapy in the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The firm says it will make the drug available in the EU immediately, initially through a named patient basis. Conditional approval of Pixuvri was granted [...]
↧